Sangamo reports updated data for gene therapy candidate ST-920
Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.
Researchers identify potential drug targets for future heart failure therapeutics
Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...
Nanomachines loaded with wine ingredients overcome gene therapy challenges
Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...